ECS Botanics (ECS.asx) is a fully licensed Australian medicinal cannabis producer, with medicinal cannabis facilities located in Victoria and Tasmania.
Our licenses include research, cultivation and manufacturing. By cultivating and manufacturing to the highest pharmaceutical quality standards that exist for medicinal cannabis, and by focusing on the lowest possible cost, ECS is a leading provider of high quality affordable medicinal cannabis.
Our operations are licensed by the Australian Office of Drug Control and compliant with the strict Single Convention on Narcotic Drugs of 1961 is an international treaty to prohibit production and supply of specific (nominally narcotic) drugs and of drugs with similar effects except under licence for specific purposes, such as medical treatment and research. We also comply with the strict Good Manufacturing Practice (GMP) regulations issued by regulators such as the Australian Therapeutic Goods (TGA) and the European authorities.
A “farm to pharma” business model.
ECS has roots in agriculture and originated from Tasmania which at its peak supplied 80% of the world opiate narcotic raw material. ECS applies a practical approach to cultivation and manufacturing which positions the business as a large scale low cost producer of high quality wholesale and final dose medicinal cannabis products.
We utilise progressive and innovative cultivation methodologies to reduce the cultivation costs of medicinal cannabis by adopting regenerative and organic agricultural practices. We do this in an environmentally sustainable way, striving for zero waste and zero net carbon emissions. By following regenerative agriculture practices and reducing expensive chemical inputs, we rebuild nature’s natural solar, mineral and water cycles and returning nutrient integrity back into the medicinal cannabis.
AS SEEN IN
SUBSCRIBE TO OUR E-NEWSLETTER
A promising new study involving patients in Canada—most of them over the age of 50—found they experienced improvements in the…
ECS Botanics Holdings has secured a 5-year $4.5 million deal to supply Polish company Alivio Spolka with the GMP manufactured…
Colombia is set to permit the export of medical cannabis flower for the first time in what could be a significant development…